Notice ID: 8a579f86781743c8a515bf7cadfe6570Presolicitation
Physics-Based Model to Quantify the Fire and Toxic Hazard of Li-Ion Batteries
Archived on August 2, 2026. Original response deadline: . Full description on SAM.gov.
Description
FR26RDI20000000066 Notice of Intent to Award a Sole Source Contract.
Pursuant to FAR 6.103-1 and inclusive of the Revolutionary FAR Overhaul (RFO) – FAR Part Deviation Guidance, The Federal Railroad Administration (FRA) intends to negotiate a single-source purchase order with Jensen Hughes, Inc. (JH) for the development of a Physics-Based Model to quantify the Fire and Toxic Hazard of Li-Ion Batteries.
This research and development effort is a continuation of critical work begun under Contract 693JJ623C000005. The original contract was awarded using a competitive Broad Agency Announcement process in 2023, BAA-2023, Topic #FRA RS-001. The initial phase focused on developing and validating computer modeling tools to quantify the fire and toxicity hazards associated with Lithium-ion Battery Energy Storage Systems (BESS) utilized in rail applications. The ultimate intent of the model is to inform the design of mitigation measures that ensure BESS are safe for the rail environment.
The overall goal of the project is to establish a systematic methodology for determining the Heat Release Rate (HRR) of complex BESS using limited cell and module level testing. Cell-level battery test data, which JH generated under Phase I, defined the failure characteristics for the model. Under this follow-on effort, module-level test data will be utilized to calibrate and validate the model.
Due to administrative and governmental delays in the internal approval process, 693JJ623C000005 expired prior to the follow-on period being executed, halting JH’s research. The intent of this purchase order is to enable JH to resume the research and further develop and validate the computer model established during Phase I.
Jensen Hughes, Inc. is uniquely qualified to satisfy this requirement, as they possess the specialized data and technical continuity developed during the initial competitive award. Awarding this requirement to any other source would result in a duplication of cost to the FRA and delays in completing Phase II.
This notice is not to request competitive proposals, and any information received from interested parties will only be considered solely for the purpose of determining whether a competitive procurement should be conducted. However, interested parties may submit a description of their firm's capabilities to satisfy this requirement, demonstrating their ability to successfully perform this effort.
Responses must be received by July 18, 2026 at 12:00 PM EST. All questions concerning this matter should be addressed directly to Ms. KeriAnne Gallagher at kerianne.gallagher@dot.gov.
Overview
Agency:
Department of TransportationFEDERAL RAILROAD ADMINISTRATION
Office:693JJ6 FEDERAL RAILROAD ADMIN
Posted:July 13, 2026
NAICS:541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Last Updated:Aug 21, 2026
PSC:AS11: TRANSPORTATION R&D SERVICES; SURFACE TRANSPORTATION, PUBLIC TRANSIT, AND RAIL; BASIC RESEARCH
Set-Aside:No Set aside used
Type:Presolicitation
Place of Performance:Baltimore, Maryland
Award Overview
Possible prior contracts
Sign in to see possible prior contracts for this requirement (matched by agency, NAICS and place of performance; not confirmed).
Contacts
Contracting Officer
Primary Contact
Gallagher, KeriAnne
Documents
No documents available.
Lifecycle
Solicitation:
FR26RDI20000000066- Pre-Solicitation
Formal solicitation typically follows within 30–60 days. (estimate)
- 2×Pre-SolicitationCurrentJul 8, 2026
Physics-Based Model to Quantify the Fire and Toxic Hazard of Li-Ion Batteries
Similar Opportunities
Title | Phase | Agency | NAICS | Set Aside | Posted | Deadline | Location |
|---|---|---|---|---|---|---|---|
The Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), Medical - Accelerated Defense Pharmaceuticals program is formally requesting information from capable companies. The objective of the program is to progress the development of existing prophylactic MCMs manufactured on existing platform technologies that support clinical safety and/or possess strong preclinical immunogenicity, safety, and efficacy data. | Special Notice | 541715 | No Set-Aside | 10/19/2026 | 11/18/2026 | Frederick, MD | |
Johns Hopkins University Applied Physics Laboratory (JHU/APL) University Affiliated Research Center (UARC) Support Services | Awarded | 541715 | No Set-Aside | 10/19/2026 | Open | Laurel, MD | |
The Department of Commerce (DOC), National Oceanic and Atmospheric Administration (NOAA), Acquisition and Grants Office (AGO) Satellite and Information Acquisition Division (SIAD) located in Silver Spring, MD, intends to award a sole source, firm-fixed-price contract to the University of Miami ((located at Office of Research Administration 1531 Brescia Avenue Coral Gables, FL 33146 -2403; UEI RQMFJGDTQ5V3), on the basis of other than full and open competition in support of the NOAA National Environmental Satellite, Data, and Information Service (NESDIS), which provides and enables oceanographic, atmospheric, and terrestrial satellite data, products, and applications for diverse organizations and users world-wide, and the Center for Satellite Applications and Research (STAR). STAR uses innovative science and applications to transform satellite observations of the Earth into meaningful information essential to NOAA. This effort is to operate and maintain NOAA’s operational ocean color system vicarious calibration capability, the Marine Optical BuoY (MOBY), in support of the Joint Polar Satellite System (JPSS) priority 2 ocean color requirements and existing NESDIS MOUs. MOBY must continue to be metrologically traceable to SI units. If awarded, the proposed subject contract action will be awarded using the "other than full and open competition" procedures at 41 U.S.C. 3304(a)(1) as implemented by RFO Subpart 6.103-1 entitled, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. This notice is not a formal Request for Proposals (RFP). However, interested parties or responsible sources who believe they can meet the operational, metrological traceability (SI units), and technical requirements of the MOBY system may submit a capability statement for consideration by the agency. Capabilities received before the closing date of this notice will be evaluated solely for the purpose of determining whether to conduct a competitive procurement. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Contracting Officer. The Government will not reimburse any costs associated with preparing or submitting a response to this notice. Concerned parties should address their concerns, issues, disagreements, and/or recommendations to the Contracting Officer for resolution. Please direct any questions regarding this Presolicitation Notice to Ms. Sarah McKim, Contracting Officer at sarah.mckim@noaa.gov with a courtesy copy to Ms. Keami Estep, Contract Specialist (affiliate), at keami.estep@noaa.gov. | Pre-Solicitation | 541715 | No Set-Aside | 10/14/2026 | 10/30/2026 | Lanai City, HI | |
Operations, Maintenance, and Sustainment Support of the Search and Rescue Satellite-Aided Tracking (SARSAT) United States Mission Control Center (USMCC) Sources Sought Notice This Sources Sought Notice (SSN) is issued solely for market research purposes to identify capable small and large business entities and does not constitute a Request for Proposal (RFP) or Request for Quotation (RFQ). This notice does not represent a commitment on the part of the Government to award a contract, nor shall the Government incur any financial obligation for information submitted in response hereto. No claim against the Government may arise from a response to this SSN or from the Government's use of any submitted information. Failure to respond to this SSN does not prohibit participation in any potential subsequent solicitation. The information contained herein is subject to revision and imposes no binding obligation upon the Government. All submitted materials shall become the property of the Government and will not be returned. Any proprietary or copyrighted information included in a response must be explicitly marked as such. Requirement: This notice is issued by the National Oceanic and Atmospheric Administration (NOAA) National Environmental Satellite, Data, and Information System (NESDIS), Office of Satellite and Mission Operations (OSPO) to identify sources capable of providing 24x7x365 Operations, Maintenance, and Sustainment Support of the Search and Rescue Satellite-Aided Tracking (SARSAT) United States Mission Control Center (USMCC). The SARSAT system relays distress signals from distress beacons carried by aviators, mariners and land-based users to Search and Rescue (SAR) services. The anticipated period of performance is a base year plus four option years. The mission of the interagency SARSAT program is to: Protect life and property by providing accurate, timely, and reliable distress alert and location information to search and rescue authorities. The U.S. SARSAT Program Management Office manages, coordinates, and implements the United States activities in the international Cospas- Sarsat search and rescue program. The mission of the SARSAT Program is fulfilled by: Collecting and distributing reliable and accurate distress alert data in a timely fashion using satellite receiving stations and a mission control center. Coordinating with national and international organizations on frequency management, satellite, emergency beacon and search and rescue issues. Maintaining a national register for 406 MHz emergency beacons. Operating, maintaining and improving the U.S SARSAT System, and representing the United States to the International Cospas-Sarsat Program. Please refer to the Draft Performance Work Statement (PWS) for detailed requirements description. NAICS Code/Size Standard: The applicable NAICS code is 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). Key Criteria: Provide 24x7x365 operation support for the USMCC, leveraging subject matter expertise to collect and distribute accurate, timely, reliable alert data. Core responsibilities include: Monitoring and operating remote satellite receiving stations as well as the mission control center. Maintaining and managing the national 406 MHz emergency beacon database. Delivering customer support and quality assurance for new and existing beacon registrations. Demonstrate comprehensive expertise and in-depth knowledge of both the domestic U.S. SARSAT initiative and the International Cospas-Sarsat Program. Coordinate frequency management, satellites, emergency beacons, and search and rescue matters with key partners: National Organization: NASA, USCG, USAF, FAA, FCC, and related agencies. International Organizations: COSPAS-SARSAT, ITU, IMO, ICAO, EUMETSAT, RTCM, RTCA, and other global bodies. Provide comprehensive technical and programmatic support to the lead U.S. agency for the U.S. SARSAT Program, while representing the United States within the international Cospas-Sarsat Program. Core support includes managing event logistics and delivering both on-site and remote meeting support for domestic and international conferences hosted on behalf of the U.S. Government. Demonstrate working knowledge of the DOC and NOAA IT security requirements for maintaining, operating, and possibly transitioning a critical national system. Required Response Information: Capable small and large business vendors are requested to provide the following information in response to this SSN announcement: Company Name/Division, mailing address, e-mail address, telephone number, and website URL (if available). A single Point-of-Contact name, title, telephone number, and e-mail address. Unique Entity ID (UEI). Please note that companies must be registered in the System for Award Management (SAM) to be considered potential sources (SAM.gov). Business Size in relation to NAICS 541715 and any SBA socio-economic certifications. Demonstrated capabilities in meeting the needs of the Key Criteria listed above. Government-Wide Contract Vehicles (e.g. GSA Advantage, NASA SEWP and/or any NOAA-Awarded Indefinite Delivery Indefinite Quantity contracts) that can support the SARSAT USMCC requirements. Please confirm whether your organization intends to submit a proposal for this requirement, and specify if you will be participating as a prime or as a subcontractor. Conflict of Interest: Please detail the extent to which the respondent is aware of any potential organizational conflict of interest issues related to this requirement. Response Format: In order to better assist in the review of responses to this SSN, respondents are encouraged to prepare a capabilities statement that does not exceed 15 pages. Response Submission Requirements and Deadline: Responses to this SSN should be submitted via e-mail attachments, received no later than 05:00 PM, EST, 28 October 2026 to: Contracting Officer: Trang Tran at Trang.tran@noaa.gov; and Contracting Specialist: Scott DeLoera at Scott.deLoera@noaa.gov. | Market Research | 541715 | No Set-Aside | 10/13/2026 | 10/28/2026 | Suitland, MD | |
INTRODUCTION: The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the NIH, an agency within the Department of Health and Human Services (DHHS); conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten the health and longevity of human lives.Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical interventions against infectious disease threats to include drug-resistant pathogens. NIAID/DMID intends to use this BAA to help address goals articulated in a number of strategic plans, such as in the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan (https://aspr.hhs.gov/PHEMCE/2024-PHEMCE-SIP/Pages/default.aspx), as well as current prioritized antimicrobial resistant threats identified by national death and infection estimates as determined by the Centers for Disease Control and Prevention’s (CDC) to prevent and control antimicrobial resistance (https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html). In addition, NIAID/DMID intends to use this BAA to encourage projects that align with the NIH priorities of enhancing rigor & reproducibility, improving biosafety and biosecurity, and the use of complementary non-animal testing methods where appropriate. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases in each of three (3) Research Areas described below and more thoroughly discussed in the attached BAA Solicitation. An offeror should carefully review the content of the BAA Solicitation No. HHS-NIH-NIAID-BAA2026-1 for the comprehensive information regarding all requirements, the technical objective of each Research Area of this BAA Solicitation, instructions regarding the proposal submission, and a description of the evaluation and award process. Please note, due to the competitive nature of the BAA Solicitation, the NIAID is unable to offer advice or feedback regarding an offeror’s specific technical approach. Offerors should exercise their professional judgment when compiling their proposals in line with the requirements and specifications of the BAA Solicitation. Research Area 001 - Vaccine Candidates: The objective is to develop vaccine candidates through an early phase clinical trial that use a needle free (i.e., alternative to classical needle and syringe, see below for description) route of delivery to protect against infections caused by viral pathogens that include but are not limited to respiratory and vector borne viruses. The scope of this vaccine research area includes the preclinical development of a needle free vaccine candidate, IND enabling studies, limited process development, Good Manufacturing Practice (GMP) compliant manufacturing, regulatory submissions to the U.S. Food and Drug Administration (FDA) and conduct of a Phase 1 or early Phase 2 clinical trial. The scope of work must include a clinical trial. Offerors must propose a single vaccine candidate for protection against a specific viral pathogen. The vaccine candidate may provide a breadth of protection against other viral strains or viruses. A strong justification is required to support (1) the proposed vaccine antigen and platform for the disease indication, (2) the use of a clinically relevant adjuvant (if needed), and (3) a clinically relevant needle free route of delivery. Research Area 002 - Therapeutic Candidates: The objective is to develop safe, effective, new therapeutic products that will improve patient outcomes against serious infectious diseases for which there are no approved therapeutics, or for those that are refractory to treatment despite appropriate antimicrobial therapy or due to pathogen resistance. Infectious diseases caused by the following viruses, bacteria and fungi pathogens are targeted: Viral hemorrhagic fever viruses (e.g., EBOV, SUDV, MARV, LASV, hantavirus) https://www.cdc.gov/viral-hemorrhagic-fevers/about/index.html Encephalitic paramyxoviruses (e.g. hendra virus, nipah virus) Picornaviruses (broad spectrum approaches that include EV68, EV70 and coxsackie virus) At least two of the following (i.e., addressed with a broad spectrum antimicrobial): susceptible and carbapenem-resistant Enterobacteriaceae (CRE), susceptible and multidrug resistant (MDR) Pseudomonas aeruginosa, and susceptible and Carbapenem-resistant Acinetobacter (CRAB), with potential to improve patient outcomes in the clinic; Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales Adjunct medical interventions to support or enhance effectiveness of antimicrobial agents to address underlying pathology that is not resolved after clearance of pathogens, may be considered. Important notice to Offerors: For this Research Area, “therapeutic” activity means curing disease by eliminating or substantially reducing infective pathogens by administering antimicrobial pharmaceutical agents, with or without a host-directed therapy. Additionally, proposed therapeutic products should consider the impact on a healthy microbiome. Preventative treatments are not included in the scope of this Research Area. A therapeutic candidate refers to an advanced lead series, preclinical candidates, or a clinical candidate, that is a new chemical entity. This includes small molecules, natural products, nucleosides, or peptides of </= 40 amino acids, monoclonal antibodies, nanobodies, nanobody conjugate/fusion products, microbiome-based therapeutics or bacteriophages. Research Area 002 will support lead optimization, pre-clinical Investigational New Drug (IND) enabling studies, and Phase 1 clinical trials (or proof of concept Phase 2 clinical trials) of lead candidates with demonstrated therapeutic activities. This includes support for traditional, novel (e.g., small molecules) and non-traditional (e.g., including but not limited to phage, and host-directed) therapeutics for infectious diseases where patients lack effective interventions, as well as therapeutics that promote host-mediated resolution of disease. The scope of support differs depending on the developmental stage of the project being proposed, which is further discussed in the BAA Solicitation. Research Area 003 - In Vitro Diagnostics The objective of Research Area 003 is to develop innovative, technology platforms that will speed detection and identification of infectious viruses covering a broad panel of virus families, including viruses causing acute infections as well as those causing chronic infections. Technology platform innovation to achieve faster actionable sequencing results (approaching 2 hr) direct from primary clinical specimens, as well as more accessible workflow and configuration (i.e., point-of-care) are preferred. Furthermore, full sample-to-answer platform solutions are preferred. The system should accept specimen volumes from 0.5 to 5 milliliters (mL). The system should include nearly full automation (little or no hands-on activity after specimen has been loaded into system). Sample preparation components of the system should yield sufficient analyte recovery from a starting titer of 10-100 genomic copies per mL of biofluid for downstream analysis, including detection, identification, and characterization of the nucleic acid material. Innovations during platform development might include, for example: Automated sample prep for high recovery from low pathogen load. Faster specimen-to-answer for total test time <2 hours. Broad viral pathogen detection capability, covering one or more members of the priority pathogen families (see below). Targeted, or even untargeted pathogen detection and identification via long-read sequencing or other detection methods. Multiple specimen throughput per run for reduced cost. Analytical sensitivity approaching 5-50 genome copies per mL of starting biofluid. Assay reconfigurability to respond rapidly to a novel pathogen in days or weeks rather than months (i.e., agnostic diagnostic solution). Priority Pathogens The diagnostic test system must detect analytes from at least one, and preferably several, of the following agents and markers: Arenaviridae (e.g., Lassa virus) Phenuviridae (e.g., Rift Valley fever virus) Peribunyayviridae (e.g., Oropouche virus) Hantaviridae (e.g., Hantavirus) Nairoviridae (e.g., Crimean Congo Hemorrhagic fever virus) Filoviridae (e.g., Sudan virus, Ebola virus, Marburg virus) Flaviviridae (e.g., Hepatitis C virus, West Nile Virus) Paramyxoviridae (e.g., Nipah virus) Togaviridae (e.g., Chikungunya virus) Picornaviridae (e.g., Enterovirus) PROPOSAL SUBMISSION: Proposals Due Date and Time – December 8, 2026, 3:00 PM Eastern Time For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by any other method is not permitted. For directions on using eCPS, go to the website: https://ecps.nih.gov and thenclick on "How to Submit." | Solicitation | 541715 | No Set-Aside | 10/09/2026 | 12/08/2026 | - |
Additional Details
Solicitation Number
FR26RDI20000000066
Archive Date
Aug 2, 2026
Office Address
WASHINGTON, DC, 20590